These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34278936)

  • 41. [Pharmacokinetic issues on cancer pharmacotherapy].
    Tanigawara Y
    Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology.
    Menz BD; Stocker SL; Verougstraete N; Kocic D; Galettis P; Stove CP; Reuter SE
    Br J Clin Pharmacol; 2021 Feb; 87(2):227-236. PubMed ID: 32430968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.
    Chatelut E; Hendrikx JJMA; Martin J; Ciccolini J; Moes DJAR
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00757. PubMed ID: 33745217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
    Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
    Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing dosing of antibiotics in critically ill patients.
    Parker SL; Sime FB; Roberts JA
    Curr Opin Infect Dis; 2015 Dec; 28(6):497-504. PubMed ID: 26382000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic drug monitoring in cancer chemotherapy.
    Bach DM; Straseski JA; Clarke W
    Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.
    Gaspar VP; Ibrahim S; Zahedi RP; Borchers CH
    J Mass Spectrom; 2021 Nov; 56(11):e4788. PubMed ID: 34738286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Determination of blood levels for oral anticancer drugs].
    van Erp NP; van der Graaf WT
    Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
    Rovithi M; Gerritse SL; Honeywell RJ; Ten Tije AJ; Ruijter R; Peters GJ; Voortman J; Labots M; Verheul HMW
    J Clin Oncol; 2019 Feb; 37(5):411-418. PubMed ID: 30586316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personalized Minimal Effective Concentration Therapy.
    Walson PD
    Clin Ther; 2023 Dec; 45(12):1289-1292. PubMed ID: 37838561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacokinet; 2005; 44(2):147-73. PubMed ID: 15656695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.
    Takada M; Goto T; Kotake T; Saito M; Kawato N; Nakai M; Gunji T; Shibakawa M
    J Clin Pharm Ther; 2005 Feb; 30(1):5-12. PubMed ID: 15658999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic drug monitoring of targeted anticancer therapy.
    Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
    Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
    Ferrer F; Tetu P; Dousset L; Lebbe C; Ciccolini J; Combarel D; Meyer N; Paci A; Bouchet S
    Crit Rev Oncol Hematol; 2024 Aug; 200():104385. PubMed ID: 38810843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
    Baselga J; Mita AC; Schöffski P; Dumez H; Rojo F; Tabernero J; DiLea C; Mietlowski W; Low C; Huang J; Dugan M; Parker K; Walk E; van Oosterom A; Martinelli E; Takimoto CH
    Clin Cancer Res; 2012 Nov; 18(22):6364-72. PubMed ID: 23014528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Personalized medicine for oral molecular-targeted anticancer drugs].
    Miura M
    Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Precision Dosing of Targeted Therapies Is Ready for Prime Time.
    Groenland SL; Verheijen RB; Joerger M; Mathijssen RHJ; Sparreboom A; Beijnen JH; Beumer JH; Steeghs N; Huitema ADR
    Clin Cancer Res; 2021 Dec; 27(24):6644-6652. PubMed ID: 34548319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.
    Knezevic CE; Clarke W
    Ther Drug Monit; 2020 Feb; 42(1):6-19. PubMed ID: 31568180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.